Cargando…

Risk of Tuberculosis Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Study

Background: In chronic obstructive pulmonary disease (COPD), inhaled corticosteroids (ICSs) are recommended for use by patients with frequent exacerbations and blood eosinophilia. However, ICSs are often inappropriately prescribed and overused. COPD studies have reported an increased risk of tubercu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Iseul, Park, Sunmin, Hong, Se Hwa, Chang, Min-Seok, Lee, Seok Jeong, Yong, Suk Joong, Lee, Won-Yeon, Kim, Sang-Ha, Lee, Ji-Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321025/ https://www.ncbi.nlm.nih.gov/pubmed/35887686 http://dx.doi.org/10.3390/jpm12071189

Ejemplares similares

Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
por: Choi, Jae-Hwa, et al.
Publicado: (2021)

Inhaled Corticosteroids and the Risk of Nontuberculous Mycobacterial Pulmonary Disease in Chronic Obstructive Pulmonary Disease: Findings from a Nationwide Population-Based Study
por: Yu, Iseul, et al.
Publicado: (2023)

Budesonide and fluticasone propionate differentially affect the airway epithelial barrier
por: Heijink, I. H., et al.
Publicado: (2016)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018)

Adherence to Long-Acting Inhaler Use for Initial Treatment and Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study
por: Suh, Hee-Sook, et al.
Publicado: (2022)

Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate
por: Provost, Karin A., et al.
Publicado: (2019)

Efficacy of intranasal fluticasone propionate and budesonide in management of allergic rhinitis—a prospective comparative study
por: Shankari, P. Kiruba, et al.
Publicado: (2021)

Budesonide and fluticasone and adrenal suppression
por: Fouda, Mona A, et al.
Publicado: (2012)

Selection of Representative Questionnaire Items from the Asthma Control Test
por: Chang, Min-Seok, et al.
Publicado: (2022)

In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices
por: Nave, Ruediger, et al.
Publicado: (2007)

Adrenal suppression in an asthmatic presenting after change from high dose inhaled fluticasone propionate to inhaled budesonide
por: Abdurahman, Zainab B, et al.
Publicado: (2010)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

Efficacy of treatment with montelukast, fluticasone propionate and budesonide liquid suspension for the prevention of recurrent asthma paroxysms in children with wheezing disorders
por: Ding, Bo, et al.
Publicado: (2019)

Fluticasone furoate/fluticasone propionate – different drugs with different properties
por: Biggadike, Keith
Publicado: (2011)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Early readmission and mortality in acute exacerbation of chronic obstructive pulmonary disease with community-acquired pneumonia
por: Shin, Beomsu, et al.
Publicado: (2018)

Fluticasone Propionate Liposomes for Pulmonary Delivery
por: Nirale, N. M., et al.
Publicado: (2009)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation
por: Ringdal, N., et al.
Publicado: (1996)

Budesonide, fluticasone propionate, and azithromycin do not modulate the membrane vesicle release by THP-1 macrophages and respiratory pathogens during macrophage infection
por: Volgers, Charlotte, et al.
Publicado: (2017)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

Polysomnographic phenotype as a risk factor for cardiovascular diseases in patients with obstructive sleep apnea syndrome: a retrospective cohort study
por: Park, Sunmin, et al.
Publicado: (2020)

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
por: Yasui, Hideki, et al.
Publicado: (2018)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis
por: Wei, Zhengbo, et al.
Publicado: (2023)

No dose effect observed with chronic fluticasone propionate on growth velocity in children
por: Lee, Laurie A., et al.
Publicado: (2020)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Degradation rates and products of fluticasone propionate in alkaline solutions
por: Tokumura, Tadakazu, et al.
Publicado: (2017)

Fluticasone-propionate: COVID-19 infection: case report
Publicado: (2020)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
por: Mills, Hilla, et al.
Publicado: (2022)

Fluticasone propionate and increased risk of pneumonia in COPD: is it PAFR-dependent?
por: Sohal, Sukhwinder Singh
Publicado: (2017)

Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease.
por: Verhoeven, G T, et al.
Publicado: (2001)

Improvement of Airflow Limitation by Fluticasone Propionate/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?
por: Akamatsu, Keiichiro, et al.
Publicado: (2011)

Comparison of the effect of high-dose inhaled budesonide and fluticasone on adrenal function in patients with severe chronic obstructive pulmonary disease
por: Fahim, Ahmed, et al.
Publicado: (2012)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Inhaled fluticasone propionate impairs pulmonary clearance of Klebsiella Pneumoniae in mice
por: Patterson, Craig M, et al.
Publicado: (2012)

Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
por: Papi, A, et al.
Publicado: (2017)

Beneficial Immunomodulatory Effects of Fluticasone Propionate in Chlamydia pneumoniae-Infected Mice
por: Paróczai, Dóra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_45kvtk57c5a0iju7qsvlsadv4e